Tersera patents expiration
1. Prialt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(1 year, 3 days from now) | |
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 days from now) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 days from now) | |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine; Analgesia; Treatment of pain
Dosage: INJECTABLE;INTRATHECAL
PRIALT family patents
2. Qmiiz Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8545879 | TERSERA | Fast disintegrating compositions of meloxicam |
Aug, 2030
(6 years from now) | |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 19 October, 2018
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
QMIIZ ODT family patents
3. Varubi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178550 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Apr, 2027
(3 years from now) | |
| US7049320 | TERSERA | NK1 antagonists |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796299 | TERSERA | NK1 antagonists |
Dec, 2022
(9 months ago) | |
| US7981905 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(3 years from now) | |
| US8404702 | TERSERA | Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(3 years from now) | |
| US7563801 | TERSERA | Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
Apr, 2027
(3 years from now) | |
| US8470842 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Jan, 2029
(5 years from now) | |
| US8361500 | TERSERA | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
Oct, 2029
(6 years from now) | |
| US9101615 | TERSERA | Intravenous formulations of neurokinin-1 antagonists |
Jul, 2032
(8 years from now) | |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
Market Authorisation Date: 01 September, 2015
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
Dosage: TABLET;ORAL
VARUBI family patents
4. Xermelo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7553840 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Dec, 2027
(4 years from now) | |
| US8193204 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use |
Feb, 2031
(7 years from now) | |
| US7709493 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Feb, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7968559 | TERSERA | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
Dec, 2027
(4 years from now) | |
| US8653094 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
Dec, 2028
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 28, 2024 |
Drugs and Companies using TELOTRISTAT ETIPRATE ingredient
Market Authorisation Date: 28 February, 2017
Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy
Dosage: TABLET;ORAL
XERMELO family patents
5. Zoladex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7220247 | TERSERA | Automatically operable safety shield system for syringes |
Apr, 2022
(1 year, 5 months ago) | |
| US7118552 | TERSERA | Automatically operable safety shield system for syringes |
Apr, 2022
(1 year, 5 months ago) | |
Drugs and Companies using GOSERELIN ACETATE ingredient
Market Authorisation Date: 11 January, 1996
Treatment: NA
Dosage: IMPLANT;IMPLANTATION
ZOLADEX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic